Humacyte, Inc. (NASDAQ:HUMA) Director Purchases $66,000.00 in Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius purchased 50,000 shares of the stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Humacyte Trading Up 33.0 %

NASDAQ HUMA opened at $1.53 on Thursday. The stock’s fifty day moving average price is $2.98 and its 200-day moving average price is $4.23. The stock has a market cap of $221.61 million, a P/E ratio of -1.14 and a beta of 1.62. Humacyte, Inc. has a 12 month low of $1.15 and a 12 month high of $9.97.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to analysts’ expectations of $0.64 million. As a group, analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vontobel Holding Ltd. bought a new position in shares of Humacyte during the fourth quarter valued at $50,000. Petros Family Wealth LLC bought a new position in Humacyte during the 4th quarter valued at about $50,000. Syon Capital LLC purchased a new stake in shares of Humacyte during the 4th quarter valued at about $54,000. Brookstone Capital Management bought a new stake in shares of Humacyte in the fourth quarter worth approximately $56,000. Finally, ACT Wealth Management LLC bought a new position in Humacyte during the fourth quarter valued at approximately $57,000. 44.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on HUMA. Benchmark reiterated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research report on Wednesday, March 12th. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Humacyte currently has a consensus rating of “Buy” and a consensus price target of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.